Publication of our economic evaluation comparing two cervical screening strategies in Belgium: HPV primary versus co-testing
Health economic evaluation of an mRNA HR-HPV assay versus a DNA HR-HPV assay for the proposed French cervical screening programme
Further evidence that rapid near-patient testing for chlamydia and gonorrhoea in sexual health clinics benefits patient care
A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada
Evaluating the benefits and costs of using an mRNA versus DNA HR-HPV assay in the National Cervical Screening Programme in the Netherlands
Modelling the impact of using a DNA compared to mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark
Estimating the costs and benefits of HR-HPV assay choice in a theoretical HPV primary cervical screening algorithm in Ontario, Canada
Evaluating the choice of HPV assay in the French cervical screening programme with a decision tree model
A cost effectiveness analysis of repeat screening for syphilis in pregnancy as an alternative screening strategy in the UK
Cost-effectiveness and impact of five different point of care strategies to preserve last line treatment for gonorrhoea
